Malaysian contract manufacturer Cell AgriTech has acquired all equipment from the Singaporean research arm of cultivated seafood firm Avant. This strategic purchase follows Avant's decision to cease its operations in Singapore amidst industry-wide financial pressures. The move significantly enhances Cell AgriTech's capacity to support the burgeoning cellular agriculture sector as it navigates a period of consolidation.
A Strategic Asset Acquisition
Cell AgriTech secured the assets after Avant Proteins, Avant's Singapore subsidiary, wound down last month due to its liabilities. The acquisition, completed at an undisclosed but competitive cost, prevents valuable industry equipment from being decommissioned. Founder Jason Ng Chin Aik stated the goal was to redeploy the assets to continue serving the cellular agriculture field.
The comprehensive purchase includes a range of lab-scale production systems, pilot-scale bioreactors, and advanced analytical tools. This equipment is vital for companies moving from early-stage research and development to pilot and commercial production phases. Cell AgriTech aims to integrate these assets seamlessly into its existing infrastructure to support a wider range of clients.
Bolstering Manufacturing Capabilities
This acquisition provides a substantial boost to Cell AgriTech's operational capabilities, which are currently running at 70-80% capacity. The new equipment adds meaningful capacity, particularly enhancing the company's analytical systems and small-scale bioprocessing abilities. This allows for more diverse and robust support for cultivated meat and seafood companies at various stages of growth.
As a dedicated contract development and manufacturing organization (CDMO), Cell AgriTech requires a full spectrum of equipment. The integration of Avant's assets strengthens its overall infrastructure and supports its ongoing expansion efforts, including plans for a second, larger facility in Singapore. The company is also concurrently building additional in-house bioreactor systems to further scale its production capabilities.
Navigating a Shifting Industry Landscape
Avant's departure from Singapore highlights the significant financial and scale-up challenges facing the cultivated meat industry. This trend has prompted a recalibration within the sector, with some companies consolidating or ceasing operations. The high costs and slower-than-expected consumer adoption have been key factors in this global market shift.
The Singaporean government has also adjusted its food strategy in response to these global trends. Citing production costs and consumer acceptance, the nation is now prioritizing research and development to make the sector more competitive long-term. This shift underscores the complex journey required to bring cultivated protein to the mainstream market.
Building the Backbone of Cultivated Meat
Cell AgriTech positions itself as a critical infrastructure provider, offering shared, ready-to-use facilities to lower entry barriers for startups. This model allows companies to focus on innovation and commercialization without incurring heavy capital expenditure on equipment. The company provides support for bioreactor capacities ranging from 200ml up to 5,000 litres.
The firm operates certified facilities in both Malaysia and Singapore, adhering to strict food safety standards like GMP and ISO 22000. It currently serves four cultivated meat and seafood clients, including notable names like Aleph Farms and Umami Bioworks. These partnerships demonstrate the growing demand for specialized manufacturing support in the alternative protein space.
Cell AgriTech's acquisition of Avant's equipment is more than a simple asset purchase; it is a strategic consolidation that strengthens its position as a key enabler in the cellular agriculture ecosystem. By providing scalable and cost-efficient manufacturing infrastructure, the company is building a crucial foundation for the industry's future. This move underscores the vital role of CDMOs in helping cultivated meat navigate its path toward commercial viability.
Source: greenqueen